CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED PURSUANT TO ITEM 601(B)(10)(IV) OF REGULATION S-K BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE...
Exhibit 10.16(b)
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED PURSUANT TO ITEM 601(B)(10)(IV) OF REGULATION S-K BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.
FIRST AMENDMENT TO THE EXCLUSIVE LICENSE AGREEMENT
UC Control Number [***]
This First Amendment (the “First Amendment”) is made effective May 21, 2021 (the “First Amendment’s Effective Date”), by and between The Regents of the University of California, a California public corporation, having its statewide administrative offices at [***] (“The Regents”), acting through The Technology Development Group of the University of California, Los Angeles (“UCLA”), located at [***], and Sana Biotechnology, Inc. (“Licensee”), a Delaware Corporation having its principal place of business at 000 X. Xxxxxx Xx., Xxxxx 000, Xxxxxxx XX 00000, and amends the license agreement with Licensee, dated March 01, 2019 with UC Agreement Control Number [***] (the “Agreement”).
RECITALS
WHEREAS, Licensee wishes to amend the development milestone and timeline set forth in Section 6.2A of the Agreement and The Regents is willing to grant an extension of the development milestone and timeline set forth in Section 6.2A of the Agreement due to effects of the COVID-19 pandemic; and
NOW THEREFORE, in consideration of the foregoing premises and the mutual promises, covenants, and agreements hereinafter set forth, all parties to this Second Amendment mutually agree to amend the Agreement as follows:
“A. [***]”
All other terms and conditions of the Agreement remain the same. This First Amendment may be executed in two or more counterparts, each of which shall be deemed an original but all of which together shall constitute one and the same instrument. Facsimile, Portable Document Format (PDF) or photocopied signatures of the Parties will have the same legal validity as original signatures.
IN WITNESS WHEREOF, both The Regents and Licensee have executed this amendment by their respective and duly authorized officers on the dates indicated below.
SANA BIOTECHNOLOGY, INC. THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
By: /s/ Xxxxxxxxx Xxxxx_________________ By: /s/ Xxxx X. Xxxxxxxxxx_________________
Name: ____Christian Hordo_____________ Name:_______Xxxx X. Xxxxxxxxxx__________
Title: ____Chief Business Officer_________ Title:____Sr. Director, Bio Pharmaceuticals____
Date: _06/11/2021____________________ Date:_06/11/2021________________________
THE REGENTS OF THE UNIVERITY OF CALIFORNIA
By: /s/ Xxxx Xxxxxxx_________________
Name:_______Xxxx Xxxxxxx_______________
Title:___AVC Technology Development Group_
Date: _06/11/21_________________________
